RxDoctor Payments Data

Barry Holcomb, MD

Pulmonary Disease · Pagosa Springs, CONPI 1134107006

Payments from drug & device makers

$506in general payments, 2019–2025

Across 24 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$100
  • GSK$52
  • United Therapeutics Corporation$48
  • Novartis$40
  • Grifols USA, LLC$36
  • Pulmonx Corporation$34
  • plus $198 from 9 others

What the payments were for

  • Food & beverage$506100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$506 in reported general payments places this provider in the 35th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$129,422
Medicare patients
658
Services billed
1,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter636$570,530
Tyvaso DpiTreprostinil19$473,627
OpsumitMacitentan21$263,030
OfevNintedanib Esylate26$236,162
Prolastin CAlpha-1-Proteinase Inhibitor13$150,021
Dupixent PenDupilumab18$119,040
Pirfenidone42$118,373
Fasenra PenBenralizumab18$98,280
XolairOmalizumab28$92,168
SymbicortBudesonide/Formoterol Fumarate228$91,308
Advair HfaFluticasone Propion/Salmeterol136$80,404
NucalaMepolizumab21$77,896
Ambrisentan22$62,561
Spiriva RespimatTiotropium Bromide84$55,596
Combivent RespimatIpratropium/Albuterol Sulfate66$43,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$52$708,138780 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$100$353,085208 claims
Actelion Pharmaceuticals US, Inc.Opsumit$29$263,03021 claims
Grifols USA, LLCProlastin C$36$150,02113 claims
AstraZenecaSymbicort, Breztri Aerosphere$29$119,620271 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Pagosa Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →